Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a large drop in short interest in January. As of January 30th, there was short interest totaling 62,681 shares, a drop of 64.2% from the January 15th total of 175,260 shares. Based on an average daily volume of 80,567 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.3% of the shares of the company are sold short. Currently, 1.3% of the shares of the company are sold short. Based on an average daily volume of 80,567 shares, the days-to-cover ratio is presently 0.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Redhill Biopharma in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On Redhill Biopharma

An institutional investor recently bought a new position in Redhill Biopharma stock. Gagnon Securities LLC purchased a new stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned approximately 0.54% of Redhill Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Stock Performance

Shares of Redhill Biopharma stock opened at $1.00 on Wednesday. Redhill Biopharma has a twelve month low of $0.91 and a twelve month high of $5.75. The firm has a market cap of $5.10 million, a P/E ratio of 0.00 and a beta of 4.91. The firm’s 50-day simple moving average is $1.20 and its 200-day simple moving average is $1.36.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.